investigational protease inhibitor

BERLIN (MedPage Today) -- Boceprevir, an investigational protease inhibitor for hepatitis C virus (HCV) infection, is effective against genotype 1 of the virus irrespective of whether it is combined with peginterferon alfa-2a or 2b.

BOSTON (MedPage Today) -- A shorter, six-month course of the investigational protease inhibitor boceprevir added to standard combination treatment appears just as effective as almost a full year of therapy for patients with a challenging subtype of hepatitis C, researchers reported here.

(MedPage Today) -- An investigational protease inhibitor aimed at blocking hepatitis C replication can double the response rate compared with standard care, researchers said.

NEW ORLEANS (MedPage Today) -- Adding an investigational protease inhibitor for hepatitis C virus (HCV) to standard treatment induced rapid and sustained virologic responses in many patients with poor responses to standard therapy alone, researchers said here.

Re-treating hepatitis C patients with standard therapy plus the investigational protease inhibitor telaprevir significantly improved the chances of eradicating the virus, researchers found.

CHICAGO (MedPage Today) -- The investigational protease inhibitor telaprevir, added to standard hepatitis C (HCV) treatment, produced a sustained virologic response in about half of patients who had previously failed with conventional therapy, a phase IIb trial showed.

WHEELING, W.Va. (MedPage Today) -- An investigational protease inhibitor for hepatitis C virus (HCV) infection showed promise in a phase II trial as add-on therapy, a researcher said.

MONTREAL (MedPage Today) -- Data presented here on two investigational protease inhibitor boosters have encouraged HIV clinicians who have been relying solely on ritonavir (Norvir).